---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-036283"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:01:50.908111+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunocore reports Q2 2024 revenue growth of 32% driven by KIMMTRAK sales of $75.3 million

## Summary
- KIMMTRAK net revenues were $75.3 million in Q2 2024, up 32% year-over-year, driven by US growth and global expansion.
- Registrational Phase 3 TEBE-AM trial for KIMMTRAK in cutaneous melanoma converted from Phase 2/3; enrollment completion expected in 1H 2026.
- First patient randomized in Phase 3 PRISM-MEL-301 trial evaluating brenetafusp + nivolumab in first-line cutaneous melanoma.
- Cash and equivalents at $859.6 million; company plans to repay $50 million loan by end of 2024.
- Net loss narrowed to $11.6 million from $17.0 million in prior year quarter.

## SEC filing metadata
- accession: 0001140361-24-036283
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036124036283/0001140361-24-036283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036124036283/ef20033789_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-036283
- JSON: https://secwatch.observer/filing/0001140361-24-036283.json
- Plain text: https://secwatch.observer/filing/0001140361-24-036283.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.